Results from two phase-3 double-blind, randomized, controlled trials, PROTECT and CONSTANT, evaluating immunogenicity and safety of the 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared to the single-antigen vaccine, Engerix ® in adults

Abstract